Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Off-the-Shelf Neoantigens is the fastest growing sector, North America is the largest market

The Global Neoantigen Targeted Therapies Market is projected for substantial growth, anticipating an increase from USD 1.99 Billion in 2025 to USD 3.23 Billion by 2031, at an 8.41% Compound Annual Growth Rate. These immunotherapeutic agents are specifically engineered to identify and eliminate tumor-specific antigens derived from DNA mutations, thereby directing the immune system precisely against cancer cells. The market's expansion is fundamentally driven by the escalating global incidence of malignancies and the urgent clinical necessity for treatment regimens that minimize off-target toxicity, ultimately aiming to enhance long-term survival through heightened specificity in oncology treatment.

However, the widespread adoption of these therapies is significantly challenged by the intricate and capital-intensive manufacturing processes required for individual patient formulations. This logistical impediment complicates the industry's capacity to meet the substantial demand indicated by recent health statistics; for instance, the American Cancer Society projected approximately 2,041,910 new cancer cases in the United States for 2025. Therefore, establishing scalable and cost-efficient production models remains a critical obstacle impeding the broader commercial expansion of this sector.

Market Drivers

The integration of bioinformatics and artificial intelligence serves as a primary catalyst for the market, enabling the precise identification of tumor-specific mutations from vast next-generation sequencing datasets. This technological convergence empowers developers to select neoantigens with the highest immunogenicity, thereby significantly enhancing the clinical efficacy of personalized vaccines compared to non-specific immunotherapies.

The clinical viability of this approach was recently substantiated by positive trial outcomes; Moderna reported in June 2024 that its investigational neoantigen therapy mRNA-4157, when combined with pembrolizumab, reduced the risk of recurrence or death by 49% in high-risk melanoma patients compared to monotherapy, confirming the maturation of computational prediction algorithms into viable therapeutic tools.

Simultaneously, the expansion of strategic partnerships and research investments is accelerating the transition of these therapies from experimental stages to commercial pipelines. Pharmaceutical entities are substantially funding mRNA and vector-based delivery platforms to overcome manufacturing bottlenecks and support late-stage trials; BioNTech, for example, projected a research and development spend of up to €2.6 billion for the 2024 financial year to advance its oncology portfolio, as stated in March 2024. This influx of capital is critical, given that the International Agency for Research on Cancer projected in 2024 that the global cancer burden is expected to rise to 35 million new cases by 2050, underscoring the immense addressable market for scalable neoantigen solutions.

Market Challenges

The principal challenging factor is the intricate and capital-intensive manufacturing process necessary for individual patient formulations, which acts as a direct impediment to the growth of the Global Neoantigen Targeted Therapies Market by preventing the scalability essential to meet global demand. Unlike 'off-the-shelf' pharmaceuticals, these personalized immunotherapies necessitate a unique production cycle for every patient, thereby eliminating standard economies of scale and resulting in prohibitively high costs of goods sold.

Consequently, manufacturers encounter severe constraints in expanding production capacity to match the rising prevalence of malignancies, which limits both market penetration and patient access. The impact of these manufacturing hurdles is evident in the difficulty companies face when transitioning from clinical development to broad commercial success. The high complexity of producing personalized treatments creates a bottleneck, allowing only a few therapies to reach a substantial volume of patients. This struggle for scalability is reflected in recent industry data: according to the Alliance for Regenerative Medicine, approximately 75 percent of the global revenue in the advanced therapy sector in 2025 was generated by fewer than 10 products, highlighting the significant friction that manufacturing limitations impose on the broader commercial expansion of personalized oncology regimens.

Market Trends

The emergence of off-the-shelf shared neoantigen therapies represents a key trend addressing the critical scalability limits inherent in personalized manufacturing. By targeting common driver mutations, such as KRAS, that appear across specific patient populations, these ready-to-use formulations eliminate the lengthy production cycles typically required for bespoke vaccines, thus enabling immediate patient access.

This streamlined model is beginning to generate substantial clinical evidence, proving that standardizing target selection can yield therapeutic benefits comparable to fully individualized regimens; Elicio Therapeutics, for instance, reported in December 2024 that its off-the-shelf candidate ELI-002 achieved a median recurrence-free survival of 16.3 months in patients with resected KRAS-mutant solid tumors, validating the efficacy of this shared-antigen approach.

Concurrently, clinical development is pivoting toward adjuvant and early-stage settings, moving beyond the historical reliance on metastatic salvage lines. This strategic shift aims to eradicate minimal residual disease by deploying neoantigen vaccines when the patient's immune system is most robust and the tumor burden is minimal, significantly increasing the likelihood of preventing relapse. This approach is yielding durable remission data in aggressive indications where standard treatments often fail, as demonstrated by BioNTech's April 2024 data, which showed that adjuvant autogene cevumeran in resected pancreatic cancer resulted in a median recurrence-free survival that was not reached in immune responders, significantly outperforming the 13.4 months observed in non-responders.

Key Market Players

• BioNtech SE
• Gritstone Bio, Inc.
• Genocea Biosciences Inc.
• Moderna Inc.
• Agenus Inc.
• Immatics NV
• Advaxis Inc
• Precision Biologics
• Gilead Sciences, Inc.
• Cellular Biomedicine Group Inc.
• Achillies Therapeutics Plc.
• Merck & Co Inc.

Report Scope

In this report, the Global Neoantigen Targeted Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neoantigen Targeted Therapies Market, by Target Disease Indication:

• Bone Cancer
• Colorectal Cancer
• Gynecological Cancer
• Non-Small Cell Lung Cancer
• Renal Cell Carcinoma

Neoantigen Targeted Therapies Market, by Neoantigens Type:

• Off-the-Shelf Neoantigens
• Personalized Neoantigens

Neoantigen Targeted Therapies Market, by Immunotherapy Type:

• Dendritic Cell Vaccines
• DNA / RNA-Based Vaccines
• Protein / Peptide-based Vaccines
• TIL-Based Therapies

Neoantigen Targeted Therapies Market, by Route of Administration:

• Intradermal
• Intravenous
• Subcutaneous

Neoantigen Targeted Therapies Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Targeted Therapies Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.